The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection

Atsufumi Kawabata,1 Mitsuhiro Kinoshita,1 Hiroyuki Nishikawa,2 Ryotaro Kuroda,1 Minoru Nishida,2 Hiromasa Araki,2 Naoki Arizono,3 Yasuo Oda,1 and Kazuaki Kakehi1

1Faculty of Pharmaceutical Sciences, Kinki University, Higashi-Osaka, Japan
2Research and Development Center, Fuso Pharmaceutical Industries Ltd., Osaka, Japan
3Department of Zoology, Kyoto Prefectural University of Medicine, Kyoto, Japan

Address correspondence to: Atsufumi Kawabata, Department of Pathophysiology and Therapeutics, Faculty of Pharmaceutical Sciences, Kinki University, 3-4-1 Kowakae, Higashi-Osaka 577-8502, Japan.
Phone: 81-6-6721-2332 ext. 3815; Fax: 81-6-6730-1394; E-mail: kawabata@phar.kindai.ac.jp.

Received for publication July 17, 2000, and accepted in revised form May 1, 2001.

Protease-activated receptor-2 (PAR-2), a receptor activated by trypsin/tryptase, modulates smooth muscle tone and exocrine secretion in the salivary glands and pancreas. Given that PAR-2 is expressed throughout the gastrointestinal tract, we investigated effects of PAR-2 agonists on mucus secretion and gastric mucosal injury in the rat. PAR-2–activating peptides triggered secretion of mucus in the stomach, but not in the duodenum. This mucus secretion was abolished by pretreatment with capsaicin, which stimulates and ablates specific sensory neurons, but it was resistant to cyclo-oxygenase inhibition. In contrast, capsaicin treatment failed to block PAR-2–mediated secretion from the salivary glands. Intravenous calcitonin gene–related peptide (CGRP) and neurokinin A markedly elicited gastric mucus secretion, as did substance P to a lesser extent. Specific antagonists of the CGRP₁ and NK₃, but not the NK₁, receptors inhibited PAR-2–mediated mucus secretion. Pretreatment with the PAR-2 agonist strongly prevented gastric injury caused by HCl-ethanol or indomethacin. Thus, PAR-2 activation triggers the cytoprotective secretion of gastric mucus by stimulating the release of CGRP and tachykinins from sensory neurons. In contrast, the PAR-2–mediated salivary exocrine secretion appears to be independent of capsaicin-sensitive sensory neurons.


Introduction

Protease-activated receptor-2 (PAR-2) (1), a G protein–coupled receptor, is activated by proteolytic unmasking of the N-terminal extracellular tethered ligand that presumably binds to the extracellular loop 2 of the receptor itself (2–4). Trypsin and mast cell tryptase are considered endogenous activators for PAR-2 (1, 2, 5). Synthetic peptides based on the receptor-activating sequence of the tethered ligand (e.g., SLIGRL for murine PAR-2) are also capable of activating PAR-2 by direct binding to the receptor (1–5). PAR-2 is involved in a variety of biological events, including modulation of smooth muscle tone (6–9) and of salivary and pancreatic (10–12) exocrine secretion. Recent in vivo studies have indicated that PAR-2 agonists can inhibit bronchoconstriction (13) and improve myocardial ischemia-reperfusion injury (14), predicting their therapeutic application. On the other hand, PAR-2 agonists, when administered locally at high doses, produce inflammation (15–17). Evidence demonstrates that PAR-2 is present in sensory neurons and triggers release of calcitonin gene–related peptide (CGRP) and substance P, resulting in neurogenic inflammation (17). This also predicts that some of the various functions of PAR-2 as described above might be mediated by neuronal mechanisms.

Given that PAR-2 is expressed throughout the gastrointestinal tract, especially by the surface epithelial cells (1, 7, 11, 18), we have focused on PAR-2 as a therapeutic target for diseases related to injury of gastrointestinal mucosa. In the present study, we examined if activation of PAR-2 could trigger mucus secretion in the stomach and duodenum, using SLIGRL-NH₂ (SLp-NH₂) and its analogue, N-trans-cinnamoyl-LIGRL-ornithine-NH₂ (tcLp-NH₂), as PAR-2 agonist. The specificity and potency of these peptides in vitro as well as in vivo have been described elsewhere (10, 16, 19–21). Furthermore, we evaluated if the PAR-2 agonist could prevent the gastric injury produced by HCl/ethanol or indomethacin in rats. Here we describe, for the first time to our knowledge, that PAR-2 activation induces secretion of mucus by triggering release of endogenous CGRP and tachykinins and also exerts gastric mucosal cytoprotection.

Methods

Animals and treatment. Male Wistar rats weighing 200–250 g (Japan SLC Inc., Shizuoka, Japan) were used throughout the present experiments. All experimental procedures were approved by the institutional Committee for the Care and Use of Laboratory Animals.

Determination of secretion of gastric and duodenal mucus (mucus glycoprotein) in vivo. We monitored luminal solu-
ble mucus that originates in insoluble (adherent) mucus (22), as described elsewhere (23). Rats were deprived of food, but not water, for 24 hours before the experiments. Under anesthesia with intraperitoneal urethane at 1.5 g/kg, the rat was laparatomized, and the pylorus was ligated. Peptides (secretagogues) or vehicle were then administered intravenously (into the femoral vein) or by mouth 1 minute after intravenous or oral administration of amastatin, an aminopeptidase inhibitor, at 2.5 µmol/kg (administration volume: 1 ml/kg). After 30 minutes, the rat was sacrificed by decapitation, and gastric luminal liquid was collected from the excised stomach. In some experiments, the esophagus was also ligated at a level of the thyroid before the agonist challenge in order to completely exclude contamination of gastric liquid with salivary mucus. When secretion of mucus in the duodenum was studied, the common bile–pancreatic duct (at a point close to the duodenum) and the duodenum (at a point 5 cm distal from the common bile–pancreatic duct) were ligated in addition to the pylorus, and duodenal luminal liquid was collected 30 minutes after the agonist challenge. The amount of gastric or duodenal luminal liquid collected was quantified by weight (milligrams). The amount of mucus (mucus glycoproteins) in the samples obtained from the stomach or duodenum was determined according to a fluorometric method employing galactose oxidase and peroxidase on the basis of the content of N-acetylgalactosaminyl and galactosyl residues in mucin molecules (23). The samples were centrifuged at 10,000 g for 30 minutes, and the supernatant was exposed to ultrafiltration (cut-off molecular weight: 10,000). The large molecular mass fraction remaining on the filter membrane was collected and lyophilized. The materials dissolved in 2 M trifluoroacetic acid (200 µl) were hydrolyzed at 100°C for 4 hours and then lyophilized. The lyophilized material was dissolved in 0.1 M Tris-HCl buffer (200 µl), and a portion (50 µl) was gently mixed with an enzyme solution (150 µl) containing galactose oxidase (2 U/ml), horseradish peroxidase (1 U/ml), and 3-(p-hydroxyphenyl)propionic acid as a fluorogenic substrate (1 mM), then incubated at 37°C for 2 hours. Fluorescence intensity at 405 nm by irradiating at a 320-nm light was measured. The amount of mucus that was represented as content of galactose that was calculated from the calibration curve obtained from fluorometric measurement using standard solution of authentic galactose.

Salivation bioassay and determination of salivary amylase and mucus in vivo. Salivation responses to secretagogues were assessed in the urethane-anesthetized rats after a 24-hour fast, as described previously (10). After the saliva in the animal’s oral cavity was removed using an aspirator, the PAR-2 agonist SLp-NH₂, in combination with amastatin, was administered intravenously as described above, and the saliva secreted was successively aspirated at 1-minute intervals for 5 minutes and quantified by weight (milligrams). The activity of amylase in the collected saliva was determined by using an assay kit (Amy- lase B test; Wako Pure Chemicals Industries, Osaka, Japan). The amount of mucus in the saliva was determined by two distinct methods. One was essentially the same method as described above for the gastrointestinal mucus (23). The other method was based on the amount of sialic acids that are abundant in salivary, but not gastric, mucin molecules (24). Briefly, the collected saliva was hydrolyzed with 0.1 N HCl, and the amount of N-acetylneuraminic acid was determined by reverse-phase HPLC after derivatization with 1,2-diamino-4,5-methylenedioxy-benzene.

Determination of gastric mucosal blood flow. Under urethane anesthesia, gastric mucosal blood flow was measured by a laser Doppler flow meter (ALF-21; Advance Co., Tokyo, Japan) in the rat after a 24-hour fast. A probe (type N; Advance Co.) was placed lightly on the surface of the corpus mucosa through a balancer (ALF-B; Advance Co.). Peptides in combination with amastatin were administered intravenously in the same manner as described above.

Drug administration schedules in inhibition experiments. Diclofenac at 9 mg/kg, a dose that is supramaximal in vivo (25), was administered intravenously 10 minutes before intravenous challenge with the PAR-2 agonist SLp-NH₂ at 1 µmol/kg in combination with intravenous amastatin at 2.5 µmol/kg. Ablation of sensory nerves was performed by administration of capsaicin as described elsewhere (17). Under pentobarbital anesthesia, capsaicin at 25, 50, and 50 mg/kg was administered subcutaneously to the rat three times, at 0, 6, and 32 hours, respectively (125 mg/kg in total), and the rat was used for experiments 10 days after the last dose. The CGRP₁ receptor antagonist CGRP₈₋₃₇ at 10 nmol/kg was administered twice subcutaneously 5 minutes before intravenous amastatin and intravenously 30 seconds after intravenous amastatin (30 seconds before intravenous secretagogues). The NK₁ receptor antagonist spantide (at 100 nmol/kg) or NK₂ receptor antagonist GR83074 (at 300 nmol/kg) was also administered twice subcutaneously 5 minutes before intravenous amastatin and intravenously 30 seconds after intravenous amastatin (30 seconds before intravenous secretagogues). The NK₁ receptor antagonist spantide (at 100 nmol/kg) or NK₂ receptor antagonist GR83074 (at 300 nmol/kg) was also administered twice subcutaneously and intravenously in the same manner. The nitric oxide synthase inhibitor N⁶-nitro-L-arginine methyl ester (L-NAME) at 30 mg/kg, a dose capable of inducing marked elevation of blood pressure (26), was administered once intravenously 5 minutes before intravenous amastatin (6 minutes before intravenous SLp-NH₂). The doses of CGRP₈₋₃₇, spantide, GR83074, and L-NAME were decided on the basis of the previous reports (17, 26–29). In all experiments, the control rats received each vehicle for inhibitors or antagonists according to the same schedules.

Evaluation of protective effect of the PAR-2 agonist in rat models for gastric injury. We used two distinct gastric injury models. After a 24-hour fast, gastric lesions were created by oral administration of 1 ml of 60% ethanol/150 mM HCl solution in unanesthetized rats without pylorus ligation. In this model, rats received intravenous amastatin at 2.5 µmol/kg and intravenous SLp-NH₂ only once, 6 and 5 minutes before the challenge with the injury inducer, respectively, and after 2 hours, were sacrificed for observation of gastric injury. The indomethacin-
induced gastric lesions were observed 7 hours after subcutaneous administration of indomethacin at 25 mg/kg (30). In this model, SLp-NH$_2$ was administered intravenously repeatedly, because a single dose of SLp-NH$_2$ at 0.5 µmol/kg produced no effect in the preliminary experiments. The first dose of SLp-NH$_2$ in combination with amastatin was administered intravenously as described above, and subsequently SLp-NH$_2$ was administered intravenously repeatedly at 2-hour intervals, resulting in four doses in all. For observation of gastric lesions, the stomach excised was opened along the greater curvature, washed, and fixed with 10% formalin solution. The area of gastric glandular mucosal lesion observed in digital photographs was measured with an image process program (Mac Aspect; Mitani Co., Chiba, Japan), in a blinded evaluation. Lesion area is expressed as a percentage of the total area of the stomach, except for the fundus. For histopathological examination of the gastric lesions induced by 60% ethanol/150 mM HCl, paraffin sections were made by a standard method and stained with hematoxylin and eosin.

Peptides and other chemicals employed. PAR-2–related peptides were prepared by a standard solid-phase synthesis procedures in Peptide Synthesis Core Facility, University of Calgary (Calgary, Alberta, Canada) or by us. The concentration, purity, and composition of the peptides were determined by HPLC, mass spectrometry, and quantitative amino acid analysis. Galactose oxidase from Dactylium dendroides, horseradish peroxidase, capsaicin, and L-NAME hydrochloride were purchased from Sigma Chemical Co. (St. Louis, Missouri, USA), and 3-(p-hydroxyphenyl)propionic acid was obtained from Dojindo Laboratories (Kumamoto, Japan). Amastatin, human CGRP, substance P, neurokinin A, human CGRP$_{8–37}$, and spantide were purchased from Peptide Institute (Minoh, Japan). Diclofenac sodium salt was from Tokyo Kasei Kogyo Company Ltd. (Tokyo, Japan), and GR83074 was from Bachem AG (Bubendorf, Switzerland). Misoprostol was purchased from Cayman Chemical (Ann Arbor, Michigan, USA). Peptides were dissolved in saline for intravenous administration and in PBS for oral administration. Diclofenac was dissolved in a 5% bicarbonate–2.5% glucose buffer. Capsaicin was suspended in a saline solution containing 10% ethanol and 10% Tween-80. All other chemicals for intravenous or oral administration were dissolved in saline.

**Statistics.** Data are represented as means with SEM, and statistical significance was analyzed by ANOVA followed by Tukey’s multiple-comparison test. P values less than 0.05 were considered significant.

**Results.** Effects of PAR-2 agonists on gastric and duodenal mucus secretion in rats in vivo. SLp-NH$_2$ at 0.02–1.0 µmol/kg, when administered intravenously in combination with amastatin (an inhibitor of aminopeptidase) at 2.5 µmol/kg, which had no effect by itself (data not shown), produced a dose-dependent increase in luminal mucus content in the stomach, without affecting total amount of luminal liquid (Figure 1a). The amount of mucus secreted after intravenous administration of SLp-NH$_2$ at 1 µmol/kg was even greater than that after intravenous administration of misoprostol, a prostaglandin E$_1$ analogue, at a maximally effective dose of 2.6 µmol/kg (Figure 1a). SLp-NH$_2$ without amastatin was also capable of triggering
mucus secretion, though it was less effective; the amount (micrograms of galactose) of soluble mucus secreted after intravenous administration of vehicle and SLp-NH2 at 0.2 and 1 μmol/kg alone was 0.15 ± 0.07, 1.80 ± 0.54, and 4.79 ± 1.19 (n = 4), respectively. On the other hand, the PAR-2 inactive control peptide LSIGRL-NH2 (LSp-NH2) at 5 μmol/kg with amastatin failed to mimic the effect of SLp-NH2 (Figure 1a). Another PAR-2 agonist, tcLp-NH2, at 1 μmol/kg was equipotent as a secretagogue for gastric mucus to SLp-NH2 at the same dose in the presence of amastatin (Figure 1a), in agreement with their relative potency as the PAR-2 agonist in other systems (21). It is also of note that SLp-NH2 at the same dose range, with amastatin, had no effect on the basal acid output in the stomach (data not shown). The increased luminal mucus in the stomach produced by systemic administration of the PAR-2 agonist is not a result of contamination with salivary mucus that is secreted in response to PAR-2 activation (10, 31), because the rat with an esophageal ligation also exhibited an increase in gastric mucus following SLp-NH2 plus amastatin (Figure 1b), the magnitude being equivalent to that in the rat with the intact esophagus (Figure 1a). SLp-NH2, but not LSp-NH2, at 1 μmol/kg in combination with amastatin at 2.5 μmol/kg was also effective by oral administration in triggering secretion of gastric mucus (Figure 1c).

SLp-NH2 when administered intravenously at 0.2–5.0 μmol/kg in combination with amastatin at 2.5 μmol/kg failed to significantly trigger mucus secretion in the duodenum (Figure 1d, upper panel). It is of interest that SLp-NH2, but not LSp-NH2, elicited an increase in the amount of luminal liquid in the duodenum (Figure 1d, lower panel).

**Effects of diclofenac on the PAR-2–mediated gastric mucus secretion in the rat.** We next tested involvement of prostanooids in the gastric mucus secretion evoked by the PAR-2 agonist SLp-NH2. Diclofenac at 9 mg/kg, a supramaximal dose that is enough to almost completely inhibit cyclo-oxygenase within 5 minutes after parenteral administration (25), did not abolish the secretion of gastric mucus due to intravenous SLp-NH2 at 1 μmol/kg plus amastatin (Figure 2a).

**Effects of capsaicin on the gastric mucus secretion and salivation exerted by the PAR-2 agonist in the rat.** We then evaluated the effect of ablation of sensory nerves by pretreatment with capsaicin on the PAR-2–mediated gastric mucus secretion, considering the most recent evidence that PAR-2 agonists stimulate the primary spinal afferrent neurons (17). Capsaicin completely abolished the PAR-2–mediated gastric mucus secretion, while it had no effect on the misoprostol-induced mucus secretion (Figure 2b), strongly suggesting involvement of activation of the capsaicin-sensitive neurons. On the other hand, salivation and secretion of proteins (amylase and mucus) from salivary glands in response to PAR-2 activation that we reported recently (10, 31) were not abolished by capsaicin (Table 1).

**Effects of CGRP, substance P, neurokinin A, and their antagonists on the basal or PAR-2–mediated gastric mucus secretion in rats in vivo.** We tested if CGRP, substance P, and neurokinin A could trigger secretion of gastric mucus in vivo, because these neuropeptides are considered major neurotransmitters in gastric capsaicin-sensitive neurons that

---

**Table 1**

Effects of capsaicin on the PAR-2 agonist–induced salivation and salivary protein secretion in the rat

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Saliva (mg)</th>
<th>Amylase (IU/g saliva)</th>
<th>Galactose^a (μg/g saliva)</th>
<th>Neu5Ac (μg/g saliva)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>71.0 ± 13.2 (9)</td>
<td>742.2 ± 73.6 (9)</td>
<td>81.8 ± 27.1 (9)</td>
<td>153.2 ± 20.1 (5)</td>
</tr>
<tr>
<td>Capsaicin</td>
<td>59.2 ± 7.2 (10)</td>
<td>9845.4 ± 162.8 (10)</td>
<td>69.4 ± 9.4 (10)</td>
<td>164.8 ± 17.8 (5)</td>
</tr>
</tbody>
</table>

The PAR-2 agonist SLp-NH2, at 1 μmol/kg in combination with amastatin at 2.5 μmol/kg was administered intravenously to the rat that had received repeated administration of capsaicin or vehicle (control). No significant difference was found between the control and capsaicin-treated groups in any parameters. The amount of saliva secreted for 5 minutes after intravenous injection of saline was negligible (less than 3 mg) in both the control and capsaicin-treated group. Numbers in parentheses show the number of rats. ^a N-acetylneuraminic acid referred to as galactose. Neu5Ac, N-acetyl neuraminic acid.
play an important role in mucosal protection (32, 33) and may be stimulated by the PAR-2 agonist as described above. CGRP, administered intravenously in a dose range of 0.028–2.8 nmol/kg, in combination with amastatin, remarkably triggered secretion of gastric mucus in a dose-dependent manner (Figure 3a, left panel). A larger dose, 28 nmol/kg, of CGRP was also tested, but failed to induce additional effect (data not shown). Neurokinin A at very low doses (0.001–0.1 nmol/kg) produced very strong effect in stimulating mucus secretion (Figure 3a, right panel). Larger doses of neurokinin A than 0.1 nmol/kg evoked no additional effect (data not shown). Thus, the order of the potency of these peptides was neurokinin A > CGRP > substance P.

We then examined the effects of some receptor antagonists for the neuropeptides on the evoked gastric mucus secretion. The effects of CGRP at 0.28 nmol/kg and neurokinin A (0.028 and 0.001 nmol/kg, respectively), when coadministered, synergistically produced marked secretion of gastric mucus (Figure 3c). The secretion of mucus exerted by the PAR-2 agonist SLp-NH$_2$ at 1 µmol/kg in combination with amastatin was inhibited by CGRP$_{8-37}$ and GR83084, but not by spantide, indicating involvement of CGRP$_1$ and NK$_2$ receptors, but not NK$_1$ receptors (Figure 3d).

**Effect of the PAR-2–related peptides on gastric mucosal blood flow in the rat.** The PAR-2 agonist SLp-NH$_2$, but not the control peptide LSp-NH$_2$, when administered intravenously at 1 µmol/kg in combination with amastatin, produced a marked increase in gastric mucosal blood flow (Figure 4).
rapid and transient increase in the gastric mucosal blood flow, an effect peaking after 1 minute and disappearing after 2 minutes (Figure 4). This PAR-2–mediated effect was not significantly reduced by the CGRP receptor antagonist CGRP8–37 (10 nmol/kg, administered two times, subcutaneously and intravenously) or by the nitric oxide synthase inhibitor L-NAME (30 mg/kg, intravenously): the maximal blood flow (percentage of the baseline value) after intravenous SLp-NH2 was 172.4 ± 10.0, 172.3 ± 24.4, and 153.7 ± 18.8 in the control group and in the groups treated with CGRP8–37 and with L-NAME, respectively (n = 3). It was also confirmed that the PAR-2–mediated increase in blood flow was resistant to GR83074 (300 nmol/kg, administered two times, subcutaneously and intravenously): the maximal value (percentage) following SLp-NH2 was 151.3 ± 8.8 and 175.3 ± 10.2 in the control and GR83074-treated groups, respectively (n = 3).

Protective effects of the PAR-2 agonist on the gastric injury produced by HCl/ethanol or indomethacin in rats. Finally, we examined the protective effect of the PAR-2 agonist on two types of rat models for gastric injury (Figure 5, a and b; Figure 5c, left; and Figure 5d). SLp-NH2, when preadministered intravenously at 0.02, 0.2, and 0.5 µmol/kg, dose dependently reduced the gastric mucosal lesion produced by 60% ethanol/150 mM HCl (Figure 5c, left). Microscopic observations of the stomach from the control rats revealed relatively well-demarcated necrotic lesions in the upper one-half to three-fourths of the mucosa, along with microhemorrhage at the base of lesions, and also showed eosinophil infiltration in the deep layer of the mucosa and submucosal tissue (Figure 5a). On the other hand, the sections of the stomach from the rat treated with SLp-NH2 at 0.5 µmol/kg showed only sheetlike desquamation of surface epithelium or necrosis in the superficial layer of the mucosa, with intact gastric glands in the middle and deep layers, and revealed no or negligible hemorrhage (Figure 5b). It is of note that the effect of the largest dose (1 µmol/kg) of SLp-NH2 was less than that of 0.5 µmol/kg and equivalent to that of 0.2 µmol/kg (Figure 5c, left), being a little distinct from the dose-related effect on mucus secretion (see Figure 1). The protective effect of SLp-NH2 at 0.5 µmol/kg was abolished by pretreatment with capsaicin (Figure 5c, right), indicating involvement of sensory neurons. Furthermore, SLp-NH2, when administered four times at 0.02, 0.2, and 0.5 µmol/kg, reduced the indomethacin-created gastric lesions in a dose-dependent manner (Figure 5d). Another PAR-2 agonist, tcLp-NH2, was not tested for the protective effect in the gastric injury models, because it was highly toxic at doses larger than 1 µmol/kg, possibly by mechanisms independent of PAR-2; the mortality in rats and mice treated with intravenous tcLp-NH2 at 5 and 15 µmol/kg, respectively, was 100% (five rats or mice out of five), while SLp-NH2, even at 50 µmol/kg, was not lethal (no rats or mice out of ten died).

Discussion

The present study, for the first time to our knowledge, demonstrates that the PAR-2 agonists administered par-
enterally or orally trigger secretion of gastric, but not duodenal, mucus through release of endogenous CGRP and tachykinins, being independent of prostanooid formation. Our data also provide evidence that exogenously applied CGRP, as well as tachykinins by themselves, are capable of triggering secretion of gastric mucus. In contrast, our results reveal that the PAR-2–mediated salivary exocrine secretion is independent of capsaicin-sensitive sensory neurons, implying the complexity of the PAR-2–mediated modulation of exocrine secretion. Finally, our data show that the PAR-2 agonist exerts strong gastric mucosal cytoprotection.

Recent studies have suggested that PAR-2 triggers secretion of saliva including amylase and mucin in salivary glands (10, 31) and of pancreatic juice including amylase in the pancreas (10–12). The PAR-2–mediated gastric mucus secretion observed in the present study supports our previous hypothesis that PAR-2 may play a general or key role in regulation of digestive exocrine secretion (10). It is clear from our data that the increase in gastric mucus content following systemic administration of the PAR-2 agonist is not due to contamination with salivary mucous. The gastric mucus secretion produced by orally administered SLp-NH2 (Figure 1c) is attributable to direct activation of PAR-2 present in gastric luminal surface or neighboring regions, as in the intestinal surface (7, 11, 18), because salivation that occurred following parenteral administration of SLp-NH2, as reported previously (10), was not seen after its oral administration (data not shown), indicating little or no significant absorption of the peptide into blood circulation. This may be beneficial for clinical application of PAR-2 agonists as gastric cytoprotective agents in the future, since side effects due to systemic distribution of the drugs could be avoided.

There is evidence that PAR-2 agonists, like prostaglandins, are proinflammatory (15–17), leading to a dilemma in the therapeutic use of PAR-2 agonists (34). The relatively decreased protective effect of the PAR-2 agonist SLp-NH2 at the maximal dose employed (1 µmol/kg) in the two gastric injury models studied (Figure 5, c and d) might reflect its proinflammatory property. Long-lasting severe neurogenic inflammation in the rat hindpaw is induced by local (subplantar) injection of SLp-NH2 at a very high dose, 500 µg/paw (16, 17). The effective dose range of SLp-NH2 for systemic (intravenous) administration, either alone or in combination with amastatin, in our study was 0.2–1.0 µmol/kg (130–650 µg/kg; approximately 32.5–162.5 µg/rat), which would be too low to induce such serious inflammation after systemic distribution. Although the different effects of PAR-2 agonists could also be related to tissue, species, or models studied, we believe that PAR-2 could be a novel target for development of gastric mucosal protective agents. Nonpeptide PAR-2 agonists that are resistant to enzymatic metabolism remain to be developed. It is also noteworthy that the PAR-2 agonist SLIGRL or SLp-NH2 do not induce contraction of pregnant (35) and nonpregnant (our unpublished data) rat myometrium that is one of the most serious side effects of prostaglandin E analogues widely used as mucosal protective agents for treatment of gastroduodenal ulcer.

Our data strongly suggest that the PAR-2 agonist stimulates the capsaicin-sensitive neurons, and CGRP and tachykinins released upon stimulation trigger secretion of mucus and exert gastric mucosal protection. Our study provides evidence that CGRP1 and NK2, but not NK1, receptors mediate the PAR-2–mediated gastric mucus secretion. The role of substance P (an endogenous NK1-preferential agonist with some NK2 activity) in mucin secretion appears to be minor in terms of the effective dose range, as compared with that of CGRP and neurokinin A, an endogenous NK2-preferential agonist. It is also of note that CGRP and neurokinin A synergistically increased mucous secretion. The gastric mucosal protection exerted by CGRP, which has been well described, is considered to be attributable to the suppressed acid output and/or increased mucosal blood flow caused by CGRP (32, 33, 36, 37). Taken together with the most recent study indicating modulation by CGRP of mucin synthesis in rat gastric mucosa (38), our results would add stimulation of mucus secretion to the list of the potential mechanisms underlying the gastric mucosal protection due to CGRP. The finding that the PAR-2 agonist caused a temporary increase in gastric mucosal blood flow in a manner independent of CGRP might imply that PAR-2 is not necessarily distributed to all CGRP neurons present in the gastric mucosa. In other words, CGRP neurons regulating gastric mucosal blood vessels might not express sufficient amount of PAR-2. Considering its rapid disappearance, the PAR-2–mediated blood flow increase may play only a minor role in the gastric mucosal cytoprotection exerted by the PAR-2 agonist. It is a little surprising that the PAR-2–mediated transient blood flow increase in the gastric mucosa was not blocked even by the nitric oxide synthase inhibitor l-NAME, because PAR-2 elicits release of endothelial nitric oxide, leading to vascular relaxation in vitro (6). However, this is consistent with the previous evidence that the transient hypotension following intravenous bolus injection of SLp-NH2 is reduced only partially by l-NAME in vivo (26). Involvement of other mechanisms or substances, including endothelium-derived hyperpolarization factor, remains to be tested. It is clear that the gastric mucosal protection exerted by PAR-2 is independent of prostanooid formation that may mediate some of effects of PAR-2 agonists in other systems (6, 13, 18), considering that the PAR-2 agonist produced diclofenac-resistant mucus secretion and attenuated the indomethacin-created gastric injury in the present study.

Interestingly, the PAR-2–mediated salivation and secretion of amylase or mucus from the salivary glands were resistant to pretreatment with capsaicin in vivo in the present study, although substance P, which the capsaicin-sensitive neurons abundantly contain in general, is known to be one of potent secretagogues in the salivary glands (39), thereby implying involvement of mechanisms distinct from those in the gastric mucosa. The detailed mechanisms responsible for the PAR-2–mediated salivary exocrine secretion are still largely open to
question, although our recent paper has suggested involvement of tyrosine kinase (31).

That the PAR-2 agonist in combination with amastatin was incapable of triggering mucus secretion in the duodenum is against our expectation, because Kong et al. (18) have shown that activation of PAR-2 produces secretion of prostaglandin E2 in isolated rat jejenum, which is a well-known secretagogue for gastrointestinal mucus. Nevertheless, the PAR-2 agonist elicited an increase in the amount of luminal liquid in the duodenum. This might be interpreted by recent evidence that a PAR-2-like receptor activated by SLP-NH2 modulates intestinal ion transport via a prostanooid-mediated mechanism (20). Thus, the action of PAR-2 agonists in the stomach and duodenum is greatly distinct.

Endogenous tryptase in mast cells and also coagulation factors VII and X in blood stream could also be a candidate for endogenous PAR-2 in the gastrointestinal tract, as described in a wide variety of tissues (13, 42), including epithelial cells in the esophagogastrointestinal tract (42), could also be a candidate for endogenous activators of PAR-2 in the stomach, as described recently (34). In conclusion, the present results imply a novel protective role for the inflammatory proteases–PAR-2 system in the gastric mucosa.